Literature DB >> 25514533

A Winogradsky-based culture system shows an association between microbial fermentation and cystic fibrosis exacerbation.

Robert A Quinn1, Katrine Whiteson1, Yan-Wei Lim1, Peter Salamon2, Barbara Bailey2, Simone Mienardi3, Savannah E Sanchez1, Don Blake3, Doug Conrad4, Forest Rohwer1.   

Abstract

There is a poor understanding of how the physiology of polymicrobial communities in cystic fibrosis (CF) lungs contributes to pulmonary exacerbations and lung function decline. In this study, a microbial culture system based on the principles of the Winogradsky column (WinCF system) was developed to study the physiology of CF microbes. The system used glass capillary tubes filled with artificial sputum medium to mimic a clogged airway bronchiole. Chemical indicators were added to observe microbial physiology within the tubes. Characterization of sputum samples from seven patients showed variation in pH, respiration, biofilm formation and gas production, indicating that the physiology of CF microbial communities varied among patients. Incubation of homogenized tissues from an explant CF lung mirrored responses of a Pseudomonas aeruginosa pure culture, supporting evidence that end-stage lungs are dominated by this pathogen. Longitudinal sputum samples taken through two exacerbation events in a single patient showed that a two-unit drop in pH and a 30% increase in gas production occurred in the tubes prior to exacerbation, which was reversed with antibiotic treatment. Microbial community profiles obtained through amplification and sequencing of the 16S rRNA gene showed that fermentative anaerobes became more abundant during exacerbation and were then reduced during treatment where P. aeruginosa became the dominant bacterium. Results from the WinCF experiments support the model where two functionally different CF microbial communities exist, the persistent Climax Community and the acute Attack Community. Fermentative anaerobes are hypothesized to be the core members of the Attack Community and production of acidic and gaseous products from fermentation may drive developing exacerbations. Treatment targeting the Attack Community may better resolve exacerbations and resulting lung damage.

Entities:  

Mesh:

Year:  2015        PMID: 25514533      PMCID: PMC4817692          DOI: 10.1038/ismej.2014.234

Source DB:  PubMed          Journal:  ISME J        ISSN: 1751-7362            Impact factor:   10.302


  78 in total

1.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

Authors:  Dieter Worlitzsch; Robert Tarran; Martina Ulrich; Ute Schwab; Aynur Cekici; Keith C Meyer; Peter Birrer; Gabriel Bellon; Jürgen Berger; Tilo Weiss; Konrad Botzenhart; James R Yankaskas; Scott Randell; Richard C Boucher; Gerd Döring
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?

Authors:  Franziska A Stressmann; Geraint B Rogers; Peter Marsh; Andrew K Lilley; Thomas W V Daniels; Mary P Carroll; Lucas R Hoffman; Graeme Jones; Collette E Allen; Nilesh Patel; Benjamin Forbes; Andrew Tuck; Kenneth D Bruce
Journal:  J Cyst Fibros       Date:  2011-06-12       Impact factor: 5.482

Review 3.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

4.  Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota.

Authors:  Amanda F Goddard; Benjamin J Staudinger; Scot E Dowd; Amruta Joshi-Datar; Randall D Wolcott; Moira L Aitken; Corinne L Fligner; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-07       Impact factor: 11.205

Review 5.  Anaerobic physiology of Pseudomonas aeruginosa in the cystic fibrosis lung.

Authors:  Max Schobert; Dieter Jahn
Journal:  Int J Med Microbiol       Date:  2010-10-16       Impact factor: 3.473

Review 6.  Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung.

Authors:  Michael Hogardt; Jürgen Heesemann
Journal:  Int J Med Microbiol       Date:  2010-10-12       Impact factor: 3.473

7.  Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology.

Authors:  Kelli L Palmer; Lauren M Mashburn; Pradeep K Singh; Marvin Whiteley
Journal:  J Bacteriol       Date:  2005-08       Impact factor: 3.490

Review 8.  Culture-based diagnostic microbiology in cystic fibrosis: can we simplify the complexity?

Authors:  Jane L Burns; Jean-Marc Rolain
Journal:  J Cyst Fibros       Date:  2013-10-03       Impact factor: 5.482

9.  Microbial decomposition of methionine and identity of the resulting sulfur products.

Authors:  W Segal; R L Starkey
Journal:  J Bacteriol       Date:  1969-06       Impact factor: 3.490

10.  Increased iron and ferritin content of sputum from patients with cystic fibrosis or chronic bronchitis.

Authors:  S W Stites; B Walters; A R O'Brien-Ladner; K Bailey; L J Wesselius
Journal:  Chest       Date:  1998-09       Impact factor: 9.410

View more
  32 in total

1.  A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.

Authors:  Manon F Pritchard; Lydia C Powell; Alison A Jack; Kate Powell; Konrad Beck; Hannah Florance; Julian Forton; Philip D Rye; Arne Dessen; Katja E Hill; David W Thomas
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Getting Our Fingers on the Pulse of Slow-Growing Bacteria in Hard-To-Reach Places.

Authors:  Tara Gallagher; Joann Phan; Katrine Whiteson
Journal:  J Bacteriol       Date:  2018-11-26       Impact factor: 3.490

3.  Stenotrophomonas maltophilia Differential Gene Expression in Synthetic Cystic Fibrosis Sputum Reveals Shared and Cystic Fibrosis Strain-Specific Responses to the Sputum Environment.

Authors:  Graham G Willsey; Korin Eckstrom; Annette E LaBauve; Lauren A Hinkel; Kristin Schutz; Robert J Meagher; John J LiPuma; Matthew J Wargo
Journal:  J Bacteriol       Date:  2019-07-10       Impact factor: 3.490

Review 4.  How can the cystic fibrosis respiratory microbiome influence our clinical decision-making?

Authors:  Geraint B Rogers; Kenneth D Bruce; Lucas R Hoffman
Journal:  Curr Opin Pulm Med       Date:  2017-11       Impact factor: 3.155

Review 5.  Moving beyond descriptive studies: harnessing metabolomics to elucidate the molecular mechanisms underpinning host-microbiome phenotypes.

Authors:  Stephanie L Bishop; Marija Drikic; Soren Wacker; Yuan Yao Chen; Anita L Kozyrskyj; Ian A Lewis
Journal:  Mucosal Immunol       Date:  2022-08-15       Impact factor: 8.701

6.  A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung.

Authors:  Lo M Sosinski; Christian Martin H; Kerri A Neugebauer; Lydia-Ann J Ghuneim; Douglas V Guzior; Alicia Castillo-Bahena; Jenna Mielke; Ryan Thomas; Marc McClelland; Doug Conrad; Robert A Quinn
Journal:  J Cyst Fibros       Date:  2021-11-22       Impact factor: 5.527

7.  What Makes Pseudomonas aeruginosa a Pathogen?

Authors:  Burkhard Tümmler
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

8.  Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease.

Authors:  Robert A Quinn; Yan Wei Lim; Tytus D Mak; Katrine Whiteson; Mike Furlan; Douglas Conrad; Forest Rohwer; Pieter Dorrestein
Journal:  PeerJ       Date:  2016-08-11       Impact factor: 2.984

9.  Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome.

Authors:  Robert A Quinn; Vanessa V Phelan; Katrine L Whiteson; Neha Garg; Barbara A Bailey; Yan Wei Lim; Douglas J Conrad; Pieter C Dorrestein; Forest L Rohwer
Journal:  ISME J       Date:  2015-12-01       Impact factor: 10.302

Review 10.  The Microbiome in Cystic Fibrosis.

Authors:  Yvonne J Huang; John J LiPuma
Journal:  Clin Chest Med       Date:  2015-12-23       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.